• Context Therapeutics held its annual shareholder meeting on June 24, 2026.
• Shareholders backed an amendment to increase authorized common shares to 300,000,000 from 200,000,000; the amendment was filed the same day.
• Shareholders ratified CohnReznick LLP as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Shareholders also authorized potential meeting adjournments to solicit additional proxies tied to the share-authorisation amendment; no adjournment was needed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-045744), on June 26, 2026, and is solely responsible for the information contained therein.